221 related articles for article (PubMed ID: 34131903)
1. Preclinical models of myocardial infarction: from mechanism to translation.
Martin TP; MacDonald EA; Elbassioni AAM; O'Toole D; Zaeri AAI; Nicklin SA; Gray GA; Loughrey CM
Br J Pharmacol; 2022 Mar; 179(5):770-791. PubMed ID: 34131903
[TBL] [Abstract][Full Text] [Related]
2. Preclinical rodent models of cardiac fibrosis.
Wang Y; Wang M; Samuel CS; Widdop RE
Br J Pharmacol; 2022 Mar; 179(5):882-899. PubMed ID: 33973236
[TBL] [Abstract][Full Text] [Related]
3. Animal models of pulmonary hypertension: Getting to the heart of the problem.
Dignam JP; Scott TE; Kemp-Harper BK; Hobbs AJ
Br J Pharmacol; 2022 Mar; 179(5):811-837. PubMed ID: 33724447
[TBL] [Abstract][Full Text] [Related]
4. The canine chronic atrioventricular block model in cardiovascular preclinical drug research.
Loen V; Vos MA; van der Heyden MAG
Br J Pharmacol; 2022 Mar; 179(5):859-881. PubMed ID: 33684961
[TBL] [Abstract][Full Text] [Related]
5. Animal models of diabetes-associated vascular diseases: an update on available models and experimental analysis.
Choi JSY; de Haan JB; Sharma A
Br J Pharmacol; 2022 Mar; 179(5):748-769. PubMed ID: 34131901
[TBL] [Abstract][Full Text] [Related]
6. Early treatment with Resolvin E1 facilitates myocardial recovery from ischaemia in mice.
Liu G; Liu Q; Shen Y; Kong D; Gong Y; Tao B; Chen G; Guo S; Li J; Zuo S; Yu Y; Yin H; Zhang L; Zhou B; Funk CD; Zhang J; Yu Y
Br J Pharmacol; 2018 Apr; 175(8):1205-1216. PubMed ID: 28925017
[TBL] [Abstract][Full Text] [Related]
7. Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options.
Bencsik P; Gömöri K; Szabados T; Sántha P; Helyes Z; Jancsó G; Ferdinandy P; Görbe A
Br J Pharmacol; 2020 Dec; 177(23):5336-5356. PubMed ID: 32059259
[TBL] [Abstract][Full Text] [Related]
8. The tandem stenosis mouse model: Towards understanding, imaging, and preventing atherosclerotic plaque instability and rupture.
Noonan J; Bobik A; Peter K
Br J Pharmacol; 2022 Mar; 179(5):979-997. PubMed ID: 33368184
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish as a tractable model of human cardiovascular disease.
Bowley G; Kugler E; Wilkinson R; Lawrie A; van Eeden F; Chico TJA; Evans PC; Noël ES; Serbanovic-Canic J
Br J Pharmacol; 2022 Mar; 179(5):900-917. PubMed ID: 33788282
[TBL] [Abstract][Full Text] [Related]
10. Mouse models for abdominal aortic aneurysm.
Golledge J; Krishna SM; Wang Y
Br J Pharmacol; 2022 Mar; 179(5):792-810. PubMed ID: 32914434
[TBL] [Abstract][Full Text] [Related]
11. Transgenic rabbit models for cardiac disease research.
Hornyik T; Rieder M; Castiglione A; Major P; Baczko I; Brunner M; Koren G; Odening KE
Br J Pharmacol; 2022 Mar; 179(5):938-957. PubMed ID: 33822374
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor in cardiovascular diseases-Clinical trials and mechanistic insights.
Bauersachs J; López-Andrés N
Br J Pharmacol; 2022 Jul; 179(13):3119-3134. PubMed ID: 34643952
[TBL] [Abstract][Full Text] [Related]
13. Rodent models of hypertension.
Jama HA; Muralitharan RR; Xu C; O'Donnell JA; Bertagnolli M; Broughton BRS; Head GA; Marques FZ
Br J Pharmacol; 2022 Mar; 179(5):918-937. PubMed ID: 34363610
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipidaemia and cardioprotection: Animal models for translational studies.
Andreadou I; Schulz R; Badimon L; Adameová A; Kleinbongard P; Lecour S; Nikolaou PE; Falcão-Pires I; Vilahur G; Woudberg N; Heusch G; Ferdinandy P
Br J Pharmacol; 2020 Dec; 177(23):5287-5311. PubMed ID: 31769007
[TBL] [Abstract][Full Text] [Related]
15. Ageing, sex, and cardioprotection.
Ruiz-Meana M; Boengler K; Garcia-Dorado D; Hausenloy DJ; Kaambre T; Kararigas G; Perrino C; Schulz R; Ytrehus K
Br J Pharmacol; 2020 Dec; 177(23):5270-5286. PubMed ID: 31863453
[TBL] [Abstract][Full Text] [Related]
16. Anti-arrhythmic investigations in large animal models of atrial fibrillation.
Saljic A; Jespersen T; Buhl R
Br J Pharmacol; 2022 Mar; 179(5):838-858. PubMed ID: 33624840
[TBL] [Abstract][Full Text] [Related]
17. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence.
Pignataro G; Cataldi M; Taglialatela M
Br J Pharmacol; 2022 May; 179(10):2149-2174. PubMed ID: 33512003
[TBL] [Abstract][Full Text] [Related]
18. Targeting G protein-coupled receptors for heart failure treatment.
Thai BS; Chia LY; Nguyen ATN; Qin C; Ritchie RH; Hutchinson DS; Kompa A; White PJ; May LT
Br J Pharmacol; 2024 Jul; 181(14):2270-2286. PubMed ID: 37095602
[TBL] [Abstract][Full Text] [Related]
19. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment.
Trapp S; Brierley DI
Br J Pharmacol; 2022 Feb; 179(4):557-570. PubMed ID: 34323288
[TBL] [Abstract][Full Text] [Related]
20. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
Korkmaz-Icöz S; Radovits T; Szabó G
Br J Pharmacol; 2018 Jan; 175(2):223-231. PubMed ID: 28213937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
